By Chris King • 06 May 2022 • 2:51
Credit: Pfizer Press Centre
Marco Cavalieri, the head of Strategy for Biological Health Threats and Vaccines of the European Medicines Agency (EMA), announced at a press conference this Thursday, May 5, that the agency plans to approve Covid-19 vaccines adapted to Omicron and other variants in September.
“Our priority is to ensure that the adapted Covid-19 vaccines are approved by September at the latest, so that they are ready for the deployment of the new vaccination campaigns in the European Union in the autumn. This would allow manufacturers to adjust their lines of production accordingly”, he specified.
“Clinical trials of the adapted vaccines must show that they are superior to the current licensed Covid-19 vaccines against Omicron and other variants”, added Cavalieri. The EMA official revealed that the main candidates for these adapted vaccines are the Moderna and Pfizer/BioNTech laboratories.
“We are working with all the manufacturers of the vaccines that are currently approved, but it’s no mystery that mRNA vaccines are way ahead of the race. That is why we’re primarily working with Moderna and Pfizer/BioNTech”, he clarified, as reported by europasur.es.
Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our
Originally from Wales, Chris spent years on the Costa del Sol before moving to the Algarve where he is a web reporter for The Euro Weekly News covering international and Spanish national news.
Got a news story you want to share? Then get in touch at [email protected]
Your email address will not be published. Required fields are marked *
Downlaod our media pack in either English or Spanish.